This is a prospective, randomised, open label, controlled pilot study to evaluate the safety and preliminary effectiveness of the ReCell Autologous Cell Harvesting Device (ReCell) for the management of chronic leg ulcers associated with venous insufficiency. Outcome will be compared between study participants receiving standard care (debridement, compression therapy) and participants receiving ReCell in addition to standard care.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
52
Hôpital Lapeyronie
Montpellier, France
Bradford Teaching Hospitals
Bradford, United Kingdom
Cambridge University Hospitals - Addenbrooke's Hospital
Cambridge, United Kingdom
Cardiff University
Cardiff, United Kingdom
Wound healing
The primary objective of the study is to assess the difference in incidence of ulcer closure (investigator assessed as complete epithelialisation without drainage) between the ReCell group and the control group.
Time frame: 12 weeks
Wounds characterization/Quality of Life
* Wound area * Wound volume * Pain * Recurrence * Health-related Quality of Life
Time frame: At each follow-up visit (1, 2, 4, 6, 8, 12, 24, 52 weeks)
Dressing Change
\- Dressing change
Time frame: At each follow-up visit (1, 2, 4, 6, 8, 12, 24, 52 weeks) until healed
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Doncaster and Bassetlaw Hospitals
Doncaster, United Kingdom
The Leeds Teaching Hospitals - James's University Hospital
Leeds, United Kingdom
University Hospital of South Manchester - Wythenshawe Hospital
Manchester, United Kingdom